RGN Stock Overview
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Repligen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$112.35 |
| 52 Week High | US$170.00 |
| 52 Week Low | US$95.48 |
| Beta | 1.21 |
| 1 Month Change | 10.42% |
| 3 Month Change | -25.07% |
| 1 Year Change | -26.16% |
| 3 Year Change | -22.21% |
| 5 Year Change | -13.58% |
| Change since IPO | 1,628.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGN | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.9% | -2.0% | 0.9% |
| 1Y | -26.2% | -5.8% | 13.2% |
Return vs Industry: RGN underperformed the German Life Sciences industry which returned -5.8% over the past year.
Return vs Market: RGN underperformed the German Market which returned 13.2% over the past year.
Price Volatility
| RGN volatility | |
|---|---|
| RGN Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: RGN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RGN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 1,778 | Olivier Loeillot | www.repligen.com |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits.
Repligen Corporation Fundamentals Summary
| RGN fundamental statistics | |
|---|---|
| Market cap | €6.15b |
| Earnings (TTM) | -€20.42m |
| Revenue (TTM) | €577.97m |
10.6x
P/S Ratio-301.3x
P/E RatioIs RGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGN income statement (TTM) | |
|---|---|
| Revenue | US$650.43m |
| Cost of Revenue | US$317.74m |
| Gross Profit | US$332.69m |
| Other Expenses | US$355.67m |
| Earnings | -US$22.98m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 51.15% |
| Net Profit Margin | -3.53% |
| Debt/Equity Ratio | 26.7% |
How did RGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 07:00 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Repligen Corporation is covered by 29 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Hugo Solvet | BNP Paribas Exane |
| Kyle Mikson | Canaccord Genuity |